SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome
Sponsor: ClinPhone, Inc.
This PHASE2 trial investigates Overactive Bladder Syndrome (OABS) and is currently completed. ClinPhone, Inc. leads this study, which shows 12 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Oct 2024 — Jun 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Sep 2023 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ClinPhone, Inc.
- Covance
- Dainippon Sumitomo Pharma America
- ICON Clinical Research
- PPD Development, LP
- Sumitomo Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .